Washington University/ Siteman Cancer Center Lead Academic Site

华盛顿大学/斯特曼癌症中心领导学术网站

• 批准号: 9198619
• 负责人: NANCY L BARTLETT
• 金额: $ 10万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-02 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9198619
• 关键词: American College of Radiology Imaging Network; American College of Surgeons Oncology Group; Area; Cancer Center; Cancer and Leukemia Group B; Clinical Trials; Clinical Trials Cooperative Group; Collaborations; Communication; Comprehensive Cancer Center; Conduct Clinical Trials; Correlative Study; Development; Diagnostic; Diagnostic Neoplasm Staging; Disease; Eastern Cooperative Oncology Group; Enrollment; Fostering; Goals; Gynecologic Oncology; Gynecologic Oncology Group; Illinois; Image; Institution; Lead; Leadership; Malignant Neoplasms; Malignant neoplasm of lung; Medical Oncology; Mentors; Mentorship; Mission; Missouri; Modality; Patients; Physicians; Play; Principal Investigator; Prognostic Marker; Radiation Oncology; Radiation Therapy Oncology Group; Radiology Specialty; Recording of previous events; Research; Research Personnel; Site; Specialist; Therapeutic Trials; Thoracic Oncology; Translational Research; Universities; Washington; Work; anticancer research; biobank; cancer therapy; collaborative environment; design; experience; improved; leukemia/lymphoma; malignant breast neoplasm; member; metropolitan; oncology; operation; professor; programs; public health relevance; tool; treatment site

DESCRIPTION (provided by applicant): The fundamental goal of the proposed Washington University/Siteman Cancer Center (WU/SCC) Lead Academic Site is to create a supportive environment that will foster 1) scientific leadership and mentorship, 2) development of cooperative group clinical trials, 3) substantial accrual to clinical trials across the entire NCTN and 4) exceptional conduct of clinical trials. Investigators at WU/SCC are committed to work to enhance the research goals of the NCTN Program and to enroll patients to NCTN trials across the Network. WU/SCC investigators have a long history of enthusiastic participation in the cooperative groups including ACOSOG, ACRIN, CALGB, GOG, and RTOG and will continue to play key roles in the newly merged groups including the Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group, and NRG Oncology. WU/SCC will have 5 U10 Principal Investigators comprising the senior leadership team including Nancy L. Bartlett, MD (Professor, Medical Oncology), Bryan F. Meyers, MD, MPH (Professor, Thoracic Oncology), Jeff M. Michalski, MD, MBA (Professor, Radiation Oncology), David G. Mutch, MD (Professor, Gynecologic Oncology) and Barry A. Siegel, MD (Professor, Radiology). All members of the senior leadership team have extensive clinical trial experience, including many years of cooperative group involvement, and are committed to providing guidance for an institution-wide cooperative group NCTN UI0. WU/SCC is consistently among the top accruing institutions in each of the cooperative groups with outstanding accrual across many disease sites. Between January 2007 and June 2012, WU/SCC accrued 1633 patients to cooperative group therapeutic trials, an average of 297 patients per year for the last 5.5 years (171 ACOSOG, 1024 CALGB/Alliance, 156 GOG, and 282 RTOG). During this same interval, 727 patients had biospecimens collected and 101 patients were accrued to advanced imaging studies through ACRIN. WU/SCC investigators are highly motivated to contribute to the scientific mission of the NCTN, particularly in the areas of breast cancer, gynecological oncology, thoracic oncology, Gl oncology, GU oncology, leukemia, and lymphoma. Strong translational science in breast cancer, lung cancer, and AML at WU/SCC, along with large institutional biorepositories, will provide many opportunities for unique contributions to correlative studies associated with cooperative group therapeutic trials. This institution-wide UIO will facilitate enhanced communication and collaboration among disease site and modality specialists and improve our potential for contributions to the NCTN operation.

描述（由申请人提供）：拟议的华盛顿大学/Siteman癌症中心（WU/SCC）牵头学术中心的基本目标是创造一个支持性环境，以促进1）科学领导和指导，2）合作组临床试验的发展，3）整个NCTN的临床试验的实质性增加 （4）临床试验的特殊实施。WU/SCC的研究人员致力于提高NCTN计划的研究目标，并在整个网络中招募患者参加NCTN试验。WU/SCC研究者长期以来一直积极参与包括ACOSOG、ACRIN、CALGB、GOG和RTOG在内的合作组，并将继续在新合并的肿瘤临床试验联盟、ECOG-ACRIN癌症研究组和NRG肿瘤学等组中发挥关键作用。WU/SCC将由5名U10主要研究者组成高级领导团队，包括Nancy L. Bartlett，MD（肿瘤内科教授），Bryan F. Meyers，MD，MPH（教授，胸部肿瘤学），Jeff M. Michalski，MD，MBA（放射肿瘤学教授），大卫G. Mutch，MD（妇科肿瘤学教授）和巴里A. Siegel，MD（放射学教授）。高级领导团队的所有成员都具有丰富的临床试验经验，包括多年的合作小组参与，并致力于为全机构合作小组NCTN UI 0提供指导。WU/SCC一直是每个合作团体中最高的应计机构之一，在许多疾病地点都有出色的应计项目。在2007年1月至2012年6月期间，WU/SCC将1633例患者纳入合作组治疗试验，在过去5.5年中平均每年297例患者（171例ACOSOG，1024例CALGB/Alliance，156例GOG和282例RTOG）。在同一时间段内，727例患者采集了生物标本，101例患者通过ACRIN进行了高级成像研究。WU/SCC研究人员非常积极地为NCTN的科学使命做出贡献，特别是在乳腺癌、妇科肿瘤学、胸部肿瘤学、GI肿瘤学、GU肿瘤学、白血病和淋巴瘤领域。WU/SCC在乳腺癌、肺癌和AML方面的强大转化科学，沿着大型机构生物储存库，将为与合作组治疗试验相关的相关研究提供许多独特贡献的机会。这一机构范围的UIO将促进加强疾病部位和模式专家之间的沟通与合作，并提高我们对NCTN运作的贡献潜力。